Why Europe Needs the Biotech Act's SPC Extension?

By Brigitte Carion Taravella, French and European patent attorney

The EU Biotech Act, proposed by the European Commission in December 2025, introduces a targeted Supplementary Protection Certificate (SPC) extension mechanism for qualifying biotech medicines — 12 additional months of exclusivity, conditioned on demonstrable investment in European clinical development and manufacturing. The proposal sits within a broader five-pillar regulatory package designed to address structural competitiveness deficits in the EU life sciences sector.

Competitive Position of the EU Life Sciences Sector

The EU’s share of global industry-sponsored clinical trials fell from 22% in 2013 to 12% in 2023, a contraction of nearly half over a decade. China’s share over the same period rose from 8% to 29%. These figures reflect a structural reorientation of R&D investment, not cyclical variation, and the trajectory has continued to steepen. The European Investment Bank (EIB) puts the annual investment gap between EU and US biotech sectors at €40 billion, a figure that contextualises the scale of policy response required.

The EFPIA analysis reinforces this framing: longer and broader protection increases expected returns on innovative products, while broader eligibility criteria increase predictability and reduce legal uncertainty — two variables that weigh heavily in location decisions for R&D-intensive investments. R&D investment increases are more than ten times higher under the broadest eligibility scenario compared to the narrowest, illustrating the sensitivity of investment flows to the precise calibration of protection parameters.

The SPC Extension Mechanism: Eligibility Criteria

The Biotech Act introduces an SPC extension of 12 months for biotech medicines satisfying all four of the following cumulative conditions:

1. New active substance distinctly different from any authorized medicinal product in the EU
2. Distinct mechanism of action with safety and efficacy at least equivalent to existing treatments for the same disease
3. Clinical trials conducted in more than two EU Member States supporting the marketing authorization
4. At least one manufacturing step (excluding packaging, testing, and certification) performed in the Union

The eligibility criteria are narrow by design. Based on EMA data covering 2004–2011, approximately one product per year would have qualified. That figure grew to five products annually over the subsequent decade and six in the most recent five-year period, tracking the expansion of the biotech pipeline. Forward projections estimate 3–5 qualifying products per year under current development patterns, potentially rising to 4–5 annually if sponsors adjust trial and manufacturing strategies in response to the incentive structure.

Genuinely novel biotechnology medicines and ATMPs representing substantive therapeutic advances are the target. Incremental modifications to existing products fall outside the scope. The extension complements the existing SPC framework rather than replacing it, adding a conditional layer of protection for the most innovation-intensive segment of the pipeline.

The economic rationale is grounded in market asymmetry. The US accounts for approximately 45% of global pharmaceutical revenues; the EU accounts for 23%. That differential creates persistent gravitational pull toward US-centric manufacturing and development strategies, and the SPC extension is calibrated to offset it sufficiently to alter investment location decisions at the margin — particularly for products where EU and US strategies are otherwise comparably viable.

Conditioning the extension on EU clinical trial activity and EU manufacturing presence means it is structured to generate concrete economic outputs: research employment and supply chain investment, along with the geographic clustering effects that tend to compound over time.

The Broader Legislative Package: Five Pillars

The SPC extension operates within a mutually reinforcing package of measures. The Commission’s own impact assessment notes that “the effect of these measures is expected to be amplified and completed by other measures set out in the Biotech Act, especially those aimed at supporting and de-risking investment in manufacturing in the EU.”

1. Clinical Trial Reforms. Authorisation timelines for multinational trials are reduced from 106 to 75 days, with harmonised ethics coordination across Member States and a lead Reference Member State model. These procedural reforms directly address the declining EU share of global trials and reduce the practical burden of satisfying the multi-country trial requirement for SPC eligibility.
2. Strategic Projects Framework. A new recognition and support mechanism for health biotechnology strategic projects incorporates accelerated permitting with a 10-month timeline, single points of contact, and facilitated access to EU funding instruments. Reducing the risk profile of large-scale manufacturing investment is the core function here — the category of investment the SPC extension is intended to incentivise.
3. Regulatory Simplification. Streamlined procedures for ATMPs, genetically modified micro-organisms (GMMs), and biosimilars aim to remove procedural barriers that currently extend time-to-market and deter investment in EU-based development pathways.
4. Investment Mobilisation. An EU Health Biotechnology Investment Pilot, developed in partnership with the EIB, targets €10 billion in mobilised investment during 2026–2027 alone — an initial response to the €40 billion annual gap identified in EIB analysis.
5. AI and Data Framework. Trusted AI testing environments and data quality accelerators to strengthen EU positioning in AI-enabled drug discovery. Modelling suggests these tools could deliver an average 14-month reduction in development timelines, with best-case savings of up to 34 months across Phase I–III trials.

The interdependencies here are functional: faster clinical trial authorisation makes the multi-country trial criterion more achievable; strategic project support reduces the capital risk associated with EU manufacturing commitments; the investment pilot provides the financing to operationalise both. The policy objective is to make dual EU-US development strategies commercially rational for companies that might otherwise consolidate operations in the larger US market.

R&D Economics and Patient Access Implications

Biologics development timelines run from 13 to 20 years, with average development costs of approximately €2.5 billion per product. Revenue generated during the protected period funds subsequent pipeline investment, including research into rare diseases and paediatric indications where commercial returns alone are insufficient to justify development expenditure. Extended protection periods function as a financing mechanism for continued innovation, not simply as a reward for past investment.

EU venture capital in biotech declined from 34% of global share in 2013 to 18% in 2022. The SPC extension, in combination with the Investment Pilot, is intended to begin reversing that trend by improving the expected return profile for EU-based development.

On patient access, the clinical trial reforms carry direct near-term implications. Expanded EU trial activity would bring an estimated 7,800 to 23,500 additional patients into trials annually, providing access to potentially transformative treatments up to 5 to 10 years before commercial launch. Independent analysis suggests that the SPC extension itself could enrol an estimated 2,200 additional patients in clinical trials under the Commission proposal, potentially rising to 49,100 under broader eligibility configurations (EFPIA, The Value and Cost of SPC Extension, June 2026). Over a longer horizon, sustained investment supports development in high-burden therapeutic areas — oncology and neurological diseases among them — where commercial viability depends on adequate protection periods, as well as rare disease research and post-market safety studies that would otherwise be commercially unviable.

Timing Considerations

Manufacturing and development location decisions for products projected to launch between 2026 and 2030 are currently being made. The lead times involved in establishing clinical trial infrastructure and qualifying manufacturing facilities mean that the window for influencing those decisions with the current legislative cycle is finite. Delay risks ceding not only individual product investments but the platform-level commitments — mRNA, ATMPs, advanced vaccines — that will shape the structure of the European biopharmaceutical sector over the following two decades.

Assessment of Trade-offs

The Commission’s impact assessment addresses the distributional effects of the SPC extension with transparency. It transfers additional originator gross profit, funded in part through delayed biosimilar market entry. The assessment concludes, however, that the net patient welfare balance is positive: biosimilar-driven healthcare savings substantially outweigh the costs attributable to SPC-related entry delays.

Independent economic modelling corroborates this framing. Under the Commission proposal, R&D investment is projected to increase by around EUR 4 billion over 15 years, rising to EUR 45 billion under the broadest eligibility scenario — a range that reflects the significant leverage that protection parameters exert on investment decisions. Across most scenarios assessed, the estimated direct economic value generated appears to outweigh the associated increase in pharmaceutical expenditure, suggesting the measure represents a net positive long-term investment for Europe.

The residual policy question concerns the level of ambition: how large an incentive policymakers wish to provide, and how they weigh innovation and patient benefits against budgetary costs?

References:

Why Europe Needs the Biotech Act’s SPC Extension?

By Brigitte Carion Taravella, French and European patent attorney